Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deleting islet autoimmunity.

Edwin Liu1, Marcella Li, Jean Jasinski

  • 1Barbara Davis Center for Childhood Diabetes, Department of Pediatrics, University of Colorado Health Sciences Center, Aurora, CO, USA.

Cell Biochemistry and Biophysics
|August 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta cell reactivity defines disease-relevant pancreatic CD8 T cells in type 1 diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Hypoxia-mediated epicardial signaling coordinates coronary angiogenesis and myocardial expansion during zebrafish ventricle maturation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Unsedated Transnasal Esophagogastroduodenoscopy for Evaluation of Celiac Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Antigen-specific immunotherapy with a CD4<sup>+</sup> T cell neoepitope restrains CD8<sup>+</sup> T cell differentiation in murine pancreatic islet grafts.

Nature communications·2026
Same author

Assessment of a standard dietitian evaluation in pediatric patients with celiac disease.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Ironing Out the Deficiency: Tracking Iron in Celiac Disease Before and After the Gluten-Free Diet.

Nutrients·2026
Same journal

From Isoprene Units to Polyprenols and Dolichols: 70 Years of Polyisoprenoid Biosynthesis Research.

Cell biochemistry and biophysics·2026
Same journal

Therapeutic Insights into the Hepatoprotective Effect of Strobilanthes callosa.

Cell biochemistry and biophysics·2026
Same journal

The Dual Role of TGF-β and Hypoxia on MMP14-Mediated Invasion in PC3 Cells.

Cell biochemistry and biophysics·2026
Same journal

Microalgae-Mediated Synthesis of Gold Nanoparticles from Indonesian Chlorella vulgaris InaCC M205 with Potential Anticancer Properties for Biomedical Application.

Cell biochemistry and biophysics·2026
Same journal

Adsorption-driven Graphene Oxide SPR Biointerfaces: Coupled Thermodynamic, Kinetic, and Optical Modeling with Effective-layer Validation.

Cell biochemistry and biophysics·2026
Same journal

Identification of Ferroptosis-related Genes Associated with the Prognosis of Hepatocellular Carcinoma.

Cell biochemistry and biophysics·2026
See all related articles

Insulin is the primary autoantigen triggering type 1 diabetes. Future therapies may target insulin-specific T cells to halt the autoimmune process before it spreads.

Area of Science:

  • Immunology
  • Endocrinology
  • Autoimmunity

Background:

  • Type 1 diabetes (T1D) involves an autoimmune attack on pancreatic beta cells.
  • Numerous autoantigens are implicated, but insulin is considered the key initiator.

Purpose of the Study:

  • To review the role of insulin as a critical autoantigen in type 1 diabetes.
  • To explore antigen-specific immunotherapies for T1D targeting insulin-reactive T cells.

Main Methods:

  • Literature review of studies on insulin autoantigenicity in T1D.
  • Analysis of current and proposed immunotherapeutic strategies.

Main Results:

  • Evidence strongly suggests insulin is the initiating autoantigen in T1D autoimmunity.

Related Experiment Videos

  • Antigen-specific therapies aim to eliminate or inactivate insulin-reactive T cells.

    • Conclusions:

    • Targeting insulin-specific T cells offers a promising strategy for T1D immunotherapy.
    • Peptide vaccines and T cell receptor immunizations are potential methods for achieving antigen-specific tolerance.